Browsing by Author "Viola, Rodrigo Fernando de Oliveira"
Now showing 1 - 1 of 1
Results Per Page
Sort Options
- Adenosine deaminase and uric acid in feline lymphomaPublication . Viola, Rodrigo Fernando de Oliveira; Vilhena, Hugo Corte-RealLymphomas represent a large and diverse group of neoplasms that originate from lymphocytes. These neoplasms usually occur in lymphoid tissues such as lymph nodes, spleen, and bone marrow. However, they can develop in almost any tissue in the body. Lymphoma is one of the most common neoplasms seen in domestic cats. Adenosine deaminase (ADA) is an enzyme with multiple functions in the organism. It has been implicated in the metabolism of purines, being responsible for catabolism of adenosine which will originate uric acid. In human and veterinary medicine, reports show that ADA increases in inflammatory, immune-mediated and neoplastic diseases. ADA has also been recognized as a marker of cell-mediated immunity and chronic inflammation. Uric acid is the final product of the purine’s pathway, it can be found in cells, tissues and is a very important nonenzymatic antioxidant. This study aimed to investigate was to investigate the serum activity of ADA and uric acid in cats with lymphoma. For that purpose, serum concentrations of ADA and uric acid were determined in the serum of 30 cats with lymphoma at diagnosis and prior to therapy, and in serum of 20 healthy control cats. The lymphoma group was composed mainly by domestic short-hair (DSH) cats, with ages ranging from 0.5 to 17 years and with lymphomas in different anatomical locations, and in different clinical stages. Cats from the control group were also mainly DSH, with ages ranging from 2 to 13 years. Cats with lymphoma presented serum concentrations of ADA (median 29.52 U/L, IQR 18.98-62.38 U/L) and uric acid (median 0.23 mg/dL, IQR 0.15-0.34 mg/dL) significantly higher (P<0.001 in both cases) than healthy controls (ADA median 14.43 U/L, IQR 10.07-23.06 U/L; uric acid median 0.10 mg/dL, IQR 0.08-0.12 mg/dL). The results obtained in our study suggest that these analytes might be useful clinical biomarkers of diagnosis, for monitoring the evolution of the disease and the response to treatment and prognosis of feline lymphoma.